<DOC>
	<DOCNO>NCT00511472</DOCNO>
	<brief_summary>A study ass safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) MK-0941 Type 2 diabetic treat basal insulin .</brief_summary>
	<brief_title>An Investigational Drug Study Adults With Type 2 Diabetes Basal Insulin ( MK-0941-006 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male female ( nonchildbearing potential ) 18 70 year age Diagnosed Type 2 Diabetes currently treat basal insulin Smokers may participate , limited 10 cigarette per day clinic must follow clinic smoking rule History Type 1 diabetes Treated peroxisome proliferatoractivated receptor ( PPAR ) agonists within 12 week prior study start History severe hypoglycemia Allergic insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>